Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fezolinetant is primarily metabolised by CYP1A2 and to a lesser extent by CYP2C9 and CYP2C19. Raltegravir is metabolised by UGT1A1 and does not inhibit or induce CYP enzymes.